Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ndelta-(N'-Sulphodiaminophosphinyl)-L-Ornithine is a synthetic small molecule derivative of L-ornithine, characterized by the addition of a sulphodiaminophosphinyl group at the delta position. It has been studied primarily as an experimental compound and is not approved for clinical use. The compound has been used in structural biology studies as an inhibitor or ligand to probe ornithine transcarbamylase (OTC), an enzyme involved in the urea cycle that catalyzes the transfer of a carbamoyl group from carbamoyl phosphate to ornithine, forming citrulline. This molecule acts as a transition-state analog or competitive inhibitor for OTC, providing insights into enzyme mechanism and structure[1][4][6]. There are no known therapeutic indications or marketed formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ndelta-(N'-Sulphodiaminophosphinyl)-L-Ornithine.